ISPR

Ispire Technology Inc. (ISPR) Q4 2026 Earnings Call Transcript

Ispire Technology NASDAQ: ISPR said it is entering fiscal 2027 with higher quarterly revenue, a reduced operating cost base and new manufacturing licenses in Malaysia, while continuing to work through legacy receivables and pursue commercialization opportunities for its nicotine technology platforms.

Q4 Revenue Increased 33% Year-over-year and 43% Sequentially to $26.7 Million Full Year Operating Cash Burn Improves by $6.8 Million, Signaling Progress Toward Cash Flow Positive Multiple Possible Revenue Catalysts Coming Online as Malaysia Manufacturing and Vapor ODM Scale Up; Joint Venture Proprietary Age-Gating and G-Mesh Technologies Advance Toward Commercialization  LOS ANGELES, CA / ACCESS Newswire / September 16, 2026 / Ispire Technology Inc. (NASDAQ:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the fourth quarter and fiscal year ended June 30, 2026. Steven Przybyla, President of Ispire, commented, "We believe fourth quarter results mark an important inflection point for the company and the turnaround we began more than a year ago.

LOS ANGELES, CA / ACCESS Newswire / September 9, 2026 / Ispire Technology Inc. (Nasdaq:ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8 am ET on Wednesday, September 16, 2026, to discuss the Company's financial results for its fiscal fourth quarter and full year ended June 30, 2026. To listen to the conference call, please dial in using the information below.

Company Strengthens U.S.-Based Leadership and Investor Communications LOS ANGELES, Aug. 17, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), today announced the appointment of Steven Przybyla as its President, effective immediately. Przybyla will also continue to serve as the Company's Chief Legal Officer and Secretary giving the Company a senior, U.S.-based executive who will speak directly to investors about both Ispire's regulatory strategy and its growth plan.

Partnership combines pharmaceutical-grade manufacturing with Ispire's global platform to accelerate entry into one of the fastest-growing nicotine segments LOS ANGELES, May 12, 2026 /PRNewswire/ --  Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced that it has entered into a joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) ("Jincheng Pharma"), a global pharmaceutical company, to manufacture and commercialize nicotine pouch products.

Ispire Technology NASDAQ: ISPR executives told investors the company's fiscal third quarter of 2026 marked a “turning point,” citing tighter operating discipline, early signs of liquidity improvement, and several near- and long-term initiatives aimed at expanding its presence in nicotine manufacturing and compliance technology markets. Get Ispire Technology alerts:Sign UpManagement highlights Malaysia platform and phased growth roadmap Co-CEO Michael Wang said the company's business has “stabilized” following a transition away from lower-quality revenue.

Ispire Technology Inc. (ISPR) Q3 2026 Earnings Call Transcript

Cash Increased Sequentially by $468,000 to $18 Million Plans to Achieve Cash Flow Positive in Second Half of Calendar Year 2026 Business Stabilized Following Strategic Repositioning Phased Roadmap Targets Billions in Addressable Market, Including ~$73B Global Vape, ~$50–70B U.S. Flavored Vape, and $24B+ Global G-Mesh Glass Technology LOS ANGELES, May 7, 2026 /PRNewswire/ -- Ispire Technology Inc. (Nasdaq: ISPR) ("Ispire," the "Company," "we," "us," or "our"), an innovator in vaping technology and precision dosing, today reported financial results for the third quarter of fiscal 2026, for the three months ended March 31, 2026. Michael Wang, Co-Chief Executive Officer of Ispire, commented, "This quarter reflects the successful stabilization of our business and with cash growing sequentially by $468,000 to $18 million, we are now executing against a phased roadmap, with near-term revenue drivers already in production and transformative technology opportunities on the horizon: Our Malaysia manufacturing is live today, giving us a 25% tariff advantage over China in a ~$73B global vape market.

LOS ANGELES, May 1, 2026 /PRNewswire/ -- Ispire Technology Inc. ("Ispire" or the "Company") (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2026. To listen to the conference call, please dial in using the information below.